Eli Lilly's ... comparison that masks true operational performance. What I find most compelling is the broad nature of the growth. While much attention focuses on Lilly's incretin franchise ...
Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep apnea, ResMed is ramping up its education to high prescribers of ...
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
They knew people who were taking Zepbound, Wegovy, Mounjaro, Ozempic. And so they piled in and the valuations, I mean, Eli Lilly is trading ... and that kind of masks for a while our understanding ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback